We use cookies. You have options. Cookies help us keep the site running smoothly and inform some of our advertising, but if you’d like to make adjustments, you can visit our Cookie Notice page for more information.
We’d like to use cookies on your device. Cookies help us keep the site running smoothly and inform some of our advertising, but how we use them is entirely up to you. Accept our recommended settings or customise them to your wishes.

Kent Groves, PhD

Vice President Global Health Strategy, Health

Kent is a Senior Vice President of Strategy, and leads Merkle’s Global Health Strategy practice. He has been consulting in the areas of pharmaceutical and animal health strategy for more than 20 years. He is published extensively in a variety of journals including, Research in Social and Administrative Pharmacy, Formulary, the Journal of Clinical Pharmacy and Therapeutics, and the Journal of Database Marketing. Kent is recognized as a subject matter expert in the area of factors influencing physician prescribing, is the author of several white papers, and most recently was the lead author for the chapter on Prescribing Behavior in Social and Behavioral Aspects of Pharmaceutical Care, 3rd Edition, published in 2016.


Kent has worked with a number of clients in the pharmaceutical, healthcare, and animal health vertical including Abbvie, AstraZeneca, BMS, Boehringer Ingelheim, Elanco, Gilead, GSK, Merck,  Novartis,  and Sanofi (Genzyme, Chattem and Merial), focusing on engagement and communication strategy in the US, Canada, Europe and Australasia. He has a PhD in Pharmaceutical Strategy and Policy from Dalhousie University in Halifax, NS, and holds the position of Assistant Professor, Clinical Pharmacy, at the James L Winkle College of Pharmacy, University of Cincinnati.

Kent's Articles, Blog Posts, Webinars and More

Amazon health

The Amazon Effect Ramps Up Competition for Personalized Health

With the announcement of Amazon Care last week, coupled with the e-commerce giant’s initial foray into the health landscape with Haven, Amazon is making good on its intent to permanently disrupt the health landscape in America.


Unintended Consequences of Colorado’s New Pricing Disclosure Legislation

A new Colorado law requires that pharmaceutical manufacturers communicate wholesale average cost (WAC) pricing details to prescribers through either primary detailing or non-personal promotion (NPP) such as email or third-party messaging. Learn more about this law here.

Blog We suggest...

Leveraging HCP Migration to Optimize Multi-Channel Spend

One of the biggest challenges that launch brands in unique therapeutic areas face is identifying the right target audience for both unbranded and branded messaging. The right audience can impact speed to market, awareness and trial, business impact, and ROI.
Blog We suggest...

What Does the Future Hold for Peer Reviewed Medicine?

Would you prescribe a drug just because other doctors “like” it? There are indications that this may already be happening, and health marketers should start thinking about what that means for them.
Blog We suggest...

How Would You Rate Your Communications to HCPs?

It is critical to move away from an ad hoc approach incorporating email into your campaign strategy, and to take a more analytic approach to the frequency, content, cadence, and targeting of your overall email communication.
Blog We suggest...

The New Role of the Pharma Rep and Raising the Digital Stakes

Given the rapidly evolving changes to our healthcare system, as well as the overwhelming volume of content that healthcare professionals (HCP) are faced with daily across channels, a defined HCP communication strategy at the therapeutic and brand level is more important than ever for the pharmaceutical indust